AZN:NYSE
AstraZeneca
155,82 $
arrow_downward
−1,59%(−2,51) 1D
155,82 $
0,00% (0,00)
bedtimePo zaprtju
Zaprto: 13. okt., 16:00:03 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za AZN …
Odpri
160,76 $
Visoka
160,83 $
Nizka
154,00 $
Tržna kapitalizacija
242,43 mrd.
Povprečni promet
2,91 mio.
Promet
0,00
Dividenda
2,07 %
Četrtletna dividenda
0,81 $
Prvi trgovalni dan brez upravičenja do dividende
6. avg. 2026
Razmerje med ceno delnice in čistim dobičkom
23,29
52-tedenski najvišji tečaj
212,71 $
52-tedenski najnižji tečaj
80,48 $
Čisti dobiček na delnico
6,69 $
Beta
0,30
Št. izdanih delnic
1,55 mrd.
Št. zaposlenih
96 tis.
Odpri
160,76 $
Visoka
160,83 $
Nizka
154,00 $
Tržna kapitalizacija
242,43 mrd.
Povprečni promet
2,91 mio.
Promet
0,00
Dividenda
2,07 %
Četrtletna dividenda
0,81 $
Prvi trgovalni dan brez upravičenja do dividende
6. avg. 2026
Razmerje med ceno delnice in čistim dobičkom
23,29
52-tedenski najvišji tečaj
212,71 $
52-tedenski najnižji tečaj
80,48 $
Čisti dobiček na delnico
6,69 $
Beta
0,30
Št. izdanih delnic
1,55 mrd.
Št. zaposlenih
96 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
TipRanks
·
pred 12 urami
AstraZeneca’s Pediatric Nexium Study Moves Toward Data Readout, Supporting Long-Term GI Franchise
Kalkine Media
·
pred 19 urami
Can AstraZeneca (LSE:AZN) Keep Its Growth Story Intact After A Mixed Run Of Trial Readouts?
Traders Union
·
pred 21 urami
AstraZeneca stock consolidates amid mixed clinical trial results and new oncology partnership
Profil
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
Vizitka: AstraZeneca
Generalni direktorPascal Soriot
Št. zaposlenih96,1 tis.
Ustanovljeno6. apr. 1999
SedežCambridge, Cambridgeshire, Združeno kraljestvo
Sektor-
Spletno mestoastrazeneca.com